Search
for
Sort by
Research 661–690 of 1000+
- Mammalian Fetal Organ Regeneration
- Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
- Deciphering principles of morphogenesis from temporal and spatial patterns on the integument
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- The concealed side of caspases: beyond a killer of cells
- The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics
- Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review
- Polycystic Ovary Syndrome-Associated Acne: The Interplay of Hyperandrogenism, Insulin Resistance, and Therapeutic Strategies
- Alopecia Areata
- Dental Rehabilitation of a Child Diagnosed With Alopecia Areata Totalis: A Case Report
- Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates
- Physiopathological role of the enzymatic complex 5α-reductase and 3α/β-hydroxysteroid oxidoreductase in the generation of progesterone and testosterone neuroactive metabolites
- Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis
- Investigating RNA-Seq-based differential gene expression during hair follicle development in Angora goat skin
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
- 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- Oral Tofacitinib in Refractory Pediatric Alopecia Areata
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure